With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

"Programs like AIM are essential to not only driving startups’ innovation journey but also reinforcing UC San Diego's role as ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia. Snippets ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...